FDA Experience With Regulation of Naloxone Products to Address the Opioid Crisis and Opportunities for Leveraging Scientific Engagement
Clinical Pharmacology & Therapeutics2020Vol. 109(3), pp. 569–572
Citations Over TimeTop 25% of 2020 papers
Abstract
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Related Papers
- → Suppression of appetitive behavior in the rat by naloxone: Lack of effect of prior morphine dependence(1979)164 cited
- → A stereoselective blockade by naloxone of opioid and non-opioid-induced granulocyte activation(1989)22 cited
- → Reducing the community-prescribed opioid load: A public health approach to the opioid epidemic(2016)1 cited
- Effect of naloxone on basic fibroblast growth factor of cerebral ischemia in rats(2009)
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)